Blair William & Co. IL Buys 29,648 Shares of OptimizeRx Corp. (NASDAQ:OPRX)

Key Points

• Blair William & Co. IL increased its stake in OptimizeRx Corp. by 4.9% in the first quarter, owning approximately 3.41% of the company, valued at $5,465,000.
• OptimizeRx reported earnings of $0.08 per share, exceeding analysts' expectations of ($0.11), along with revenues of $21.93 million for the quarter.
• Wall Street analysts have generally given OptimizeRx a favorable outlook, with nine analysts rating it as a "buy" and an average target price of $10.81.

Blair William & Co. IL increased its position in shares of OptimizeRx Corp. (NASDAQ:OPRX - Free Report) by 4.9% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 631,031 shares of the company's stock after buying an additional 29,648 shares during the period. Blair William & Co. IL owned 3.41% of OptimizeRx worth $5,465,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC bought a new position in shares of OptimizeRx in the 1st quarter worth about $33,000. Wells Fargo & Company MN increased its holdings in OptimizeRx by 33.3% in the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock worth $54,000 after purchasing an additional 2,797 shares in the last quarter. Graham Capital Management L.P. acquired a new position in OptimizeRx in the fourth quarter valued at approximately $81,000. BNP Paribas Financial Markets boosted its holdings in shares of OptimizeRx by 504.6% during the 4th quarter. BNP Paribas Financial Markets now owns 22,308 shares of the company's stock worth $108,000 after buying an additional 18,618 shares in the last quarter. Finally, Corton Capital Inc. acquired a new stake in shares of OptimizeRx during the 4th quarter worth approximately $110,000. Institutional investors and hedge funds own 76.47% of the company's stock.

OptimizeRx Stock Performance

Shares of OptimizeRx stock traded up $4.46 during trading hours on Friday, reaching $17.30. The company had a trading volume of 2,332,311 shares, compared to its average volume of 227,436. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.82 and a quick ratio of 2.82. OptimizeRx Corp. has a one year low of $3.78 and a one year high of $18.22. The firm has a market cap of $319.96 million, a PE ratio of -32.04, a price-to-earnings-growth ratio of 5.77 and a beta of 1.33. The business has a fifty day simple moving average of $13.51 and a 200 day simple moving average of $9.86.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.11) by $0.19. OptimizeRx had a positive return on equity of 4.53% and a negative net margin of 9.42%. The business had revenue of $21.93 million during the quarter, compared to the consensus estimate of $18.69 million. On average, analysts anticipate that OptimizeRx Corp. will post -0.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

OPRX has been the topic of a number of research reports. Citigroup reiterated an "outperform" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Wall Street Zen upgraded shares of OptimizeRx from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Stifel Nicolaus boosted their price objective on OptimizeRx from $16.00 to $18.00 and gave the stock a "buy" rating in a research report on Friday. B. Riley reaffirmed a "buy" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Finally, Roth Capital reissued a "buy" rating on shares of OptimizeRx in a report on Friday. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $11.06.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.